Dailypharm Live Search Close

'Eutropin·Biktarvy' price drop amid sales hike

By Lee, Tak-Sun | translator Hong, Ji Yeon

24.11.05 05:23:31

가나다라 0
Has completed negotiation with the HIRA…adjusted prices have been confirmed through the review committee


 ▲Product photos of Eutropin and Biktarvy.


Due to the increased volume of usage, drug pricing for 'Eutropin Inj (somatropin, LG Chem)' and 'Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide, Gilead Science),' which recently showed a sales hike, is expected to be reduced.

Sources said on November 5th that the Health Insurance Review and Assessment Service (HIRA) recently agreed on drug pricing adjustment of these products through the 'Type-Na' negotiation.

As a result, the final adjusted prices will be listed on the reimbursement list following a review from the Health Insurance Policy Review Committee.

Eutropin has been a top-selling growth hormone drug in the Korean market. 'Eutropin S Pen,' intro

Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)